Loading
Everything in development, the medicines held by this cancer's subtypes, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for Plasmablastic lymphoma, drawn from the whole corpus: 0 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
Nothing recorded in development for this cancer yet.
No randomised trial has been run in plasmablastic lymphoma, and the regimens in use are chosen by analogy with other aggressive lymphomas and with myeloma.
There is no surface target. Every advance in B-cell lymphoma since 1997 has depended on CD20 or CD19, and this disease expresses neither reliably.
Half of patients have HIV, and the disease is a common first presentation of undiagnosed infection, so part of the burden belongs to HIV testing rather than to oncology.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 5 changes by month →When this page itself was last checked or edited.
Across 1,153 SEER and 1,822 National Cancer Database patients, incidence was 0.07 per 100,000 a year, median overall survival among those given multi-agent chemotherapy was 58.6 months, and HIV status had no significant effect on survival.
The cells look like plasma cells and the surface markers agree with that appearance, so the differential diagnosis includes myeloma with plasmablastic features rather than other lymphomas. What separates them is the clinical picture: a rapidly growing mass, usually in the mouth or jaw or the gut, in a younger person, often with HIV, with Epstein-Barr virus in the cells and a very high proliferation index. HIV testing belongs in every work-up.
Among 248 patients treated with chemotherapy in the SEER registries between 2010 and 2016, three-year overall survival was 54 per cent, and disease starting in the mouth carried better survival than other sites.
The first series described an aggressive lymphoma of the oral cavity in people with HIV whose cells had a plasma cell phenotype and did not carry CD20.